-
1 Comment
Advaxis, Inc is currently in a long term downtrend where the price is trading 11.8% below its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.3.
Advaxis, Inc's total revenue rose by 53733.3% to $2M since the same quarter in the previous year.
Its net income has increased by 49.4% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 62.3% to $-3M since the same quarter in the previous year.
Based on the above factors, Advaxis, Inc gets an overall score of 4/5.
| Exchange | OTCQX |
|---|---|
| CurrencyCode | USD |
| ISIN | US0076244062 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 4M |
|---|---|
| PE Ratio | None |
| Beta | nan |
| Target Price | 4 |
| Dividend Yield | None |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ADXS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
